BR112016026773A2 - domínios variáveis de imunoglobulina aperfeiçoados - Google Patents

domínios variáveis de imunoglobulina aperfeiçoados

Info

Publication number
BR112016026773A2
BR112016026773A2 BR112016026773A BR112016026773A BR112016026773A2 BR 112016026773 A2 BR112016026773 A2 BR 112016026773A2 BR 112016026773 A BR112016026773 A BR 112016026773A BR 112016026773 A BR112016026773 A BR 112016026773A BR 112016026773 A2 BR112016026773 A2 BR 112016026773A2
Authority
BR
Brazil
Prior art keywords
amino acid
acid residue
variable domains
immunoglobulin variable
improved immunoglobulin
Prior art date
Application number
BR112016026773A
Other languages
English (en)
Inventor
Boutton Carlo
Buyse Marie-Ange
Original Assignee
Ablynx Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175523&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112016026773(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ablynx Nv filed Critical Ablynx Nv
Priority to BR122018009619-5A priority Critical patent/BR122018009619B1/pt
Publication of BR112016026773A2 publication Critical patent/BR112016026773A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Abstract

a presente invenção se refere a um domio vh, em que: (i) resíduo de aminoácido na posição 112 é k ou q; e/ou (ii) o resíduo de aminoácido na posição 89 é t; e/ou (iii) o resíduo de aminoácido na posição 89 é l e o resíduo de aminoácido na posição 110 é k ou q; e (iv) em cada um dos casos de (i) a (iii), o aminoácido na posição 11 é preferivelmente v; e no qual o referido domínio vh contém uma extensão c-terminal (x)n, onde n é 1 a 10, de preferência 1 a 5, tal como 1, 2, 3, 4 ou 5 (de preferência 1 ou 2, tal como 1); e cada x é um resíduo de aminoácido (preferencialmente de ocorrência natural) que é escolhido independentemente e de preferência escolhido independentemente do grupo constituído por alanina (a), glicina (g), valina (v), leucina (l) ou isoleucina (i).
BR112016026773A 2014-05-16 2015-05-13 domínios variáveis de imunoglobulina aperfeiçoados BR112016026773A2 (pt)

Priority Applications (1)

Application Number Priority Date Filing Date Title
BR122018009619-5A BR122018009619B1 (pt) 2014-05-16 2015-05-13 Domínios variáveis de imunoglobulina aperfeiçoados

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461994552P 2014-05-16 2014-05-16
US201461014015P 2014-06-18 2014-06-18
US201462040167P 2014-08-21 2014-08-21
US201462047560P 2014-09-08 2014-09-08
US201562133600P 2015-03-16 2015-03-16
PCT/EP2015/060643 WO2015173325A2 (en) 2014-05-16 2015-05-13 Improved immunoglobulin variable domains

Publications (1)

Publication Number Publication Date
BR112016026773A2 true BR112016026773A2 (pt) 2017-12-12

Family

ID=53175523

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122018009619-5A BR122018009619B1 (pt) 2014-05-16 2015-05-13 Domínios variáveis de imunoglobulina aperfeiçoados
BR112016026773A BR112016026773A2 (pt) 2014-05-16 2015-05-13 domínios variáveis de imunoglobulina aperfeiçoados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR122018009619-5A BR122018009619B1 (pt) 2014-05-16 2015-05-13 Domínios variáveis de imunoglobulina aperfeiçoados

Country Status (14)

Country Link
EP (4) EP3693386A1 (pt)
AU (6) AU2015261536B2 (pt)
BR (2) BR122018009619B1 (pt)
CA (1) CA2948076A1 (pt)
DK (2) DK3248986T3 (pt)
ES (2) ES2912069T3 (pt)
HR (2) HRP20220400T1 (pt)
HU (2) HUE050007T2 (pt)
LT (2) LT3143042T (pt)
PL (2) PL3248986T3 (pt)
PT (2) PT3143042T (pt)
RS (2) RS60717B1 (pt)
SI (2) SI3143042T1 (pt)
WO (1) WO2015173325A2 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3693386A1 (en) 2014-05-16 2020-08-12 Ablynx NV Immunoglobulin variable domains
CA3226056A1 (en) 2015-01-21 2016-07-28 Inhibrx, Inc. Non-immunogenic single domain antibodies
CA3005082A1 (en) * 2015-11-12 2017-05-18 Ablynx Nv Improved p2x7 receptor binders and polypeptides comprising the same
NO2768984T3 (pt) 2015-11-12 2018-06-09
PL3374392T3 (pl) 2015-11-13 2022-03-28 Ablynx Nv Ulepszone domeny zmienne immunoglobuliny wiążące albuminę surowicy
CN114605530A (zh) 2015-11-18 2022-06-10 埃博灵克斯股份有限公司 改进的血清白蛋白结合剂
UA125337C2 (uk) 2015-11-18 2022-02-23 Мерк Шарп І Доум Корп. Ctla4-зв'язувальні речовини
BR112018010085A2 (pt) 2015-11-18 2018-11-13 Merck Sharp & Dohme ligantes de pd1/ctla4
SG11201804178YA (en) 2015-11-18 2018-06-28 Merck Sharp & Dohme Pd1 and/or lag3 binders
WO2017137579A1 (en) 2016-02-12 2017-08-17 Ablynx Nv Method for the production of immunoglobulin single variable domains
CN107400166A (zh) * 2016-05-19 2017-11-28 苏州康宁杰瑞生物科技有限公司 针对ctla4的单域抗体及其衍生蛋白
RU2765809C2 (ru) 2016-06-23 2022-02-03 Аблинкс Н.В. Усовершенствованные фармакокинетические анализы для одиночных вариабельных доменов иммуноглобулина
US11840569B2 (en) 2016-11-16 2023-12-12 Ablynx N.V. T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta
CN117164710A (zh) 2016-12-07 2023-12-05 埃博灵克斯股份有限公司 改进的血清白蛋白结合免疫球蛋白单可变结构域
JP7300385B2 (ja) 2017-01-17 2023-06-29 アブリンクス エン．ヴェー． 改善された血清アルブミン結合剤
EP3571225A1 (en) 2017-01-17 2019-11-27 Ablynx NV Improved serum albumin binders
US11261260B2 (en) 2017-06-02 2022-03-01 Merck Patent Gmbh ADAMTS binding immunoglobulins
US11155607B2 (en) 2017-07-19 2021-10-26 Vib Vzw Serum albumin binding agents
CN111315784A (zh) 2017-10-31 2020-06-19 非营利性组织佛兰芒综合大学生物技术研究所 新的抗原结合嵌合蛋白及其方法和用途
US20220289837A1 (en) 2019-04-30 2022-09-15 Vib Vzw Cystic Fibrosis Transmembrane Conductance Regulator Stabilizing Agents
CA3158991A1 (en) 2019-11-27 2021-06-03 Vib Vzw Positive allosteric modulators of the calcium-sensing receptor
BR112022009799A2 (pt) 2019-12-06 2022-08-16 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina alvejando tnfalfa e il-23
BR112022010231A2 (pt) 2019-12-06 2022-09-06 Ablynx Nv Polipeptídeos compreendendo domínios variáveis únicos de imunoglobulina direcionados a tnfalfa e ox40l
JP2023504914A (ja) 2019-12-09 2023-02-07 アブリンクス・エヌ・フェー Ｉｌ－１３およびｔｓｌｐを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
AR120698A1 (es) 2019-12-09 2022-03-09 Ablynx Nv Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp
WO2021123360A1 (en) 2019-12-20 2021-06-24 Vib Vzw Nanobody exchange chromatography
WO2021156490A2 (en) 2020-02-06 2021-08-12 Vib Vzw Corona virus binders
US20230087785A1 (en) 2020-02-25 2023-03-23 Vib Vzw Leucine-Rich Repeat Kinase 2 Allosteric Modulators
AU2021246890A1 (en) 2020-03-30 2022-12-01 Ablynx Nv Method for the production and purification of multivalent immunoglobulin single variable domains
WO2022003156A1 (en) 2020-07-02 2022-01-06 Oncurious Nv Ccr8 non-blocking binders
MX2023003522A (es) 2020-09-25 2023-04-19 Ablynx Nv Polipeptidos que comprenden dominios variables unicos de inmunoglobulina que se dirigen a il-13 y ox40l.
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
CA3201219A1 (en) 2020-12-04 2022-06-09 Mir Ali Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
TW202241947A (zh) 2020-12-18 2022-11-01 比利時商艾伯霖克斯公司 包含靶向磷脂醯肌醇蛋白聚糖—３和ｔ細胞受體的免疫球蛋白單可變結構域的多肽
JP2023553694A (ja) 2020-12-18 2023-12-25 アブリンクス エン．ヴェー． ＩＬ－６およびＴＮＦ－αを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド
KR20230122084A (ko) 2020-12-18 2023-08-22 아블린쓰 엔.브이. Tcr 알파/베타 반응성에 기초한 t 세포 동원 폴리펩타이드
GB202020502D0 (en) 2020-12-23 2021-02-03 Vib Vzw Antibody composistion for treatment of corona virus infection
CN117794566A (zh) 2021-02-05 2024-03-29 Vib研究所 沙贝病毒结合剂
EP4288095A1 (en) 2021-02-05 2023-12-13 Vib Vzw Sarbecovirus binders
WO2022175532A1 (en) 2021-02-19 2022-08-25 Vib Vzw Cation-independent mannose-6-phosphate receptor binders
WO2023016828A2 (en) 2021-07-30 2023-02-16 Vib Vzw Cation-independent mannose-6-phosphate receptor binders for targeted protein degradation
WO2023093899A1 (zh) * 2021-11-29 2023-06-01 江苏恒瑞医药股份有限公司 经修饰的蛋白或多肽
WO2023111266A1 (en) 2021-12-17 2023-06-22 Ablynx Nv POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123
WO2023135198A1 (en) 2022-01-12 2023-07-20 Vib Vzw Human ntcp binders for therapeutic use and liver-specific targeted delivery
WO2023198848A1 (en) 2022-04-13 2023-10-19 Vib Vzw An ltbr agonist in combination therapy against cancer
WO2023222825A1 (en) 2022-05-18 2023-11-23 Vib Vzw Sarbecovirus spike s2 subunit binders
WO2023240156A1 (en) 2022-06-08 2023-12-14 Tidal Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles, and methods of synthesis and use thereof
US20240109965A1 (en) 2022-06-14 2024-04-04 Ablynx N.V. Immunoglobulin single variable domains targeting t cell receptor
WO2024023271A1 (en) 2022-07-27 2024-02-01 Ablynx Nv Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024068744A1 (en) 2022-09-27 2024-04-04 Vib Vzw Antivirals against human parainfluenza virus

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100081792A1 (en) 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
WO2003035695A2 (en) 2001-07-26 2003-05-01 Tanox, Inc. Agents that activate or inhibit toll-like receptor 9
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
SI1517921T1 (sl) 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
FR2846667B1 (fr) 2002-11-06 2004-12-31 Pasteur Institut Fragments variables d'anticorps de camelides a chaine unique diriges contre le peptide beta-amyloide 1-42 et leurs applications pour le diagnostic et le traitement des maladies neuroagregatives
CA2505325C (en) 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
ES2542330T3 (es) 2003-01-10 2015-08-04 Ablynx N.V. Polipéptidos terapéuticos, homólogos de los mismos, fragmentos de los mismos y su uso en modular la agregación mediada por plaquetas
EP2053062A1 (en) 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
KR20070039911A (ko) 2004-06-01 2007-04-13 도만티스 리미티드 증강된 혈청 반감기를 가지는 이특이성 융합 항체
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
MX2007006593A (es) 2004-12-02 2008-03-04 Domantis Ltd Anticuerpos de dominio simple anti-il 1r1 y sus usos terapeuticos.
NZ555464A (en) 2004-12-02 2010-03-26 Domantis Ltd Bispecific domain antibodies targeting serum albumin and glp-1 or pyy
SG184709A1 (en) 2005-05-18 2012-10-30 Ablynx Nv Improved nanobodies™ against tumor necrosis factor-alpha
CA2960105A1 (en) 2005-05-20 2006-11-23 Ablynx Nv Single domain vhh antibodies against von willebrand factor
WO2006129843A2 (en) 2005-05-31 2006-12-07 Canon Kabushiki Kaisha Bispecific capturing molecule
US20090155283A1 (en) 2005-12-01 2009-06-18 Drew Philip D Noncompetitive Domain Antibody Formats That Bind Interleukin 1 Receptor Type 1
CA2629850A1 (en) 2005-12-01 2007-06-07 Domantis Limited Competitive domain antibody formats that bind interleukin 1 receptor type 1
FR2894741B1 (fr) 2005-12-08 2009-12-04 Centre Nat Etd Spatiales Chaine de reception par satellite
US20100047171A1 (en) 2006-01-24 2010-02-25 Roland Beckmann Fusion Proteins That Contain Natural Junctions
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
AU2007328900A1 (en) 2006-12-05 2008-06-12 Ablynx N.V. Peptides capable of binding to serum proteins
CN101796072B (zh) 2007-05-24 2014-09-24 埃博灵克斯股份有限公司 用于治疗骨疾病和病症的针对rank-l的氨基酸序列以及包括其的多肽
SI2158315T1 (sl) * 2007-06-25 2016-05-31 Esbatech, An Alcon Biomedical Research Unit Llc Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
AU2008328785A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
JP2011517561A (ja) 2008-03-31 2011-06-16 グラクソ グループ リミテッド 薬物融合体および複合体
AU2009237662A1 (en) 2008-04-17 2009-10-22 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
DE102008023620A1 (de) 2008-05-15 2009-11-19 Mettler-Toledo (Albstadt) Gmbh Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf
WO2009138494A2 (en) * 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
NZ589036A (en) 2008-05-16 2012-07-27 Ablynx Nv AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
WO2010042815A2 (en) 2008-10-09 2010-04-15 Duke University Vhh antibody fragments for use in the detection and treatment of cancer
NZ595344A (en) 2009-03-27 2013-09-27 Glaxo Group Ltd Drug fusions and conjugates
WO2010130832A2 (en) 2009-05-15 2010-11-18 Ablynx N.V. Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
ES2804450T3 (es) 2009-07-10 2021-02-08 Ablynx Nv Método para la producción de dominios variables
US8306355B2 (en) 2009-07-13 2012-11-06 Sharp Laboratories Of America, Inc. Methods and systems for reducing compression artifacts
US20110117113A1 (en) 2009-10-09 2011-05-19 Gerald Beste Immunoglobulin single variable domain directed against human cxcr4 and other cell associated proteins and methods to generate them
US8962807B2 (en) * 2009-12-14 2015-02-24 Ablynx N.V. Single variable domain antibodies against OX40L, constructs and therapeutic use
JP5914353B2 (ja) 2009-12-23 2016-05-11 エスバテック − ア ノバルティス カンパニー エルエルシー 免疫原性を減少させるための方法
BR112012022102A2 (pt) 2010-03-03 2017-01-10 Boehringer Ingelheim Int polipeptídeos de ligação a a-beta.
CA2800292A1 (en) 2010-04-30 2011-11-03 Ablynx Nv Amino acid sequences of nanobodies directed against p19 subunit of the heterodimeric cytokine il-23
BR112012029588A2 (pt) 2010-05-20 2017-07-25 Ablynx Nv materiais biológicas relacionados a her3.
WO2011161266A1 (en) 2010-06-25 2011-12-29 Ablynx Nv Improved immunoglobulin single variable domains and constructs thereof directed against cxcr4
JP2013145769A (ja) 2010-08-04 2013-07-25 Kri Inc 異方性希土類ボンド磁石とその製造方法
CN103917560B (zh) 2011-03-28 2017-05-24 埃博灵克斯股份有限公司 双特异性抗‑cxcr7免疫球蛋白单可变结构域
WO2012175740A1 (en) 2011-06-23 2012-12-27 Ablynx Nv Immunoglobulin single variable domains directed against ige
KR20220114104A (ko) 2011-06-23 2022-08-17 아블린쓰 엔.브이. 면역글로불린 단일 가변 도메인을 수반하는 어세이에서 비특이적 단백질 간섭을 예측하고 검출하고 감소시키는 기법
HUE047238T2 (hu) 2011-06-23 2020-04-28 Ablynx Nv Szérumalbuminhoz kötõdõ fehérjék
CA2845029A1 (en) * 2011-08-17 2013-02-21 Glaxo Group Limited Modified proteins and peptides
CN106046161B (zh) 2011-09-30 2019-09-13 埃博灵克斯股份有限公司 与C-Met相关的生物物质
EP2627773B1 (en) 2011-10-17 2017-06-14 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US20130129727A1 (en) 2011-11-17 2013-05-23 Nanjingjinsirui Science & Technology Biology Corporation Methods and systems for increasing protein stability
SI2809681T1 (sl) 2012-01-31 2019-04-30 Regeneron Pharmaceuticals, Inc. Protitelesa anti-asic1 in njihova uporaba
TWI641619B (zh) 2012-06-25 2018-11-21 美商再生元醫藥公司 抗－ｅｇｆｒ抗體及其用途
WO2014043509A2 (en) 2012-09-13 2014-03-20 Novartis Ag Antigen binding molecule with terminal modifications
US9667316B2 (en) 2013-05-17 2017-05-30 The Boeing Company Aircraft data transmission using phase separation
EP3693386A1 (en) 2014-05-16 2020-08-12 Ablynx NV Immunoglobulin variable domains

Also Published As

Publication number Publication date
EP3702369A1 (en) 2020-09-02
EP3143042A2 (en) 2017-03-22
RS63085B1 (sr) 2022-04-29
WO2015173325A8 (en) 2016-12-29
EP3693386A1 (en) 2020-08-12
PL3143042T3 (pl) 2020-11-16
WO2015173325A3 (en) 2016-02-18
AU2022279374A1 (en) 2023-01-19
AU2020202570A1 (en) 2020-05-07
HUE050007T2 (hu) 2020-11-30
SI3143042T1 (sl) 2020-08-31
EP3248986A2 (en) 2017-11-29
BR122018009619B1 (pt) 2024-01-02
CA2948076A1 (en) 2015-11-19
PT3248986T (pt) 2022-04-05
ES2815572T3 (es) 2021-03-30
PL3248986T3 (pl) 2022-05-16
PT3143042T (pt) 2020-09-01
EP3143042B1 (en) 2020-06-10
AU2020202855B2 (en) 2022-12-08
HUE058008T2 (hu) 2022-06-28
DK3248986T3 (da) 2022-04-04
AU2020202570B2 (en) 2022-12-08
HRP20200966T1 (hr) 2020-10-16
AU2015261536B2 (en) 2020-05-07
AU2022279373A1 (en) 2023-01-19
AU2018204226A1 (en) 2018-07-05
LT3248986T (lt) 2022-03-25
HRP20220400T1 (hr) 2022-05-27
WO2015173325A2 (en) 2015-11-19
EP3248986A3 (en) 2017-12-20
DK3143042T3 (da) 2020-08-31
EP3248986B1 (en) 2022-01-26
AU2020202855A1 (en) 2020-05-21
RS60717B1 (sr) 2020-09-30
ES2912069T3 (es) 2022-05-24
LT3143042T (lt) 2020-07-27
SI3248986T1 (sl) 2022-04-29
AU2015261536A1 (en) 2016-11-17

Similar Documents

Publication Publication Date Title
BR112016026773A2 (pt) domínios variáveis de imunoglobulina aperfeiçoados
PH12016502282A1 (en) Improved immunoglobulin variable domains
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
BR112017009467A2 (pt) composição de limpeza
BR112016024780A2 (pt) composições e métodos relacionados com construtos de fc manipulados
BR112016024494A8 (pt) análogo de peptídeo e seu uso
BR112017003582A2 (pt) anticorpos, composições e usos
BR112017009623A2 (pt) composição de limpeza
CO2018000410A2 (es) Moléculas de anticuerpo que se unen a cd79
EA201692467A1 (ru) Вакцины против вируса гриппа и их применения
BR112013020500A2 (pt) anticorpo isolado, recombinante ou purificado
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
BR112017015833A2 (pt) compostos anti-senescência e usos dos mesmos
BR112017022073A2 (pt) método para purificação de proteína
WO2016061504A3 (en) Recombinant antibodies that recongnize the c-terminal domains of ebola virus nucleoprotein
EA201790558A1 (ru) Композиция с пониженной иммуногенностью
DOP2017000260A (es) Piroglutamato de vortioxetina
BR112021025438A2 (pt) Composições de proteínas anti-vegf e métodos para produzir as mesmas
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
SV2017005585A (es) Peptidos lipidados resistentes a proteasas
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
BR112012013581A8 (pt) vacinas de malária baseadas em ferlinas apicomplexas, proteínas semelhantes a ferlinas e outras proteínas que contêm o domínio c2
MX362058B (es) Péptido pntx(19) sintético, composición farmacéutica y uso.
BR112018074874A2 (pt) composição cosmética antissinais, uso da composição, método de tratamento antissinais e dispositivo de aplicação

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]